Celltrion Healthcare said an antiviral drug candidate is moving along in trials as a potential treatment for coronavirus 2019 (COVID-19).
Although it has an infliximab biosimilar being tested in the CATALYST trial for potential use in patients with coronavirus disease 2019 (COVID-19), Celltrion Healthcare said today it has an antiviral antibody treatment candidate in a phase 1 study for patients with COVID-19 and that is expected to be completed by the end of the third quarter of this year.
The COVID-19 drug candidate treatment has shown promise in neutralizing several coronavirus-related strains, including the mutated G-variant strain of severe acute respiratory syndrome coronavirus 2 (D614G variant), the company said in a statement. Further in-human studies across Europe are planned.
The phase 1 study follows a new drug application approval from the Republic of Korea Ministry of Food and Drug Safety. Celltrion officials also said they expect the agent will be tested as a form of preventive therapy for COVID-19.
Trial Details
The phase 1 trial will enroll 32 healthy volunteers who have not had a COVID-19 diagnosis and evaluate safety of the antiviral antibody treatment. Following a further in-human phase 1 trial in Europe, Celltrion anticipates expanding the investigation through phase 2/3 trials in patients with mild and moderate COVID-19.
Additional investigation is planned in use of the antiviral as a preventive measure in individuals who come into proximity with patients with COVID-19, such as health care workers.
“The initiation of this in-human clinical trial is a key milestone in the development of our antiviral antibody treatment,” said Sang Joon Lee, PhD, senior executive vice president of Celltrion. “We were encouraged by the positive safety and efficacy results in our preclinical studies, and we are now ready to move into in-human clinical trials as we originally planned. We remain committed to carrying out local and global clinical studies with the goal of commencing mass production of the therapeutic antibody treatment in the latter half of this year.”
EC Approves First MS Biosimilar; Coherus Receives CRL for Neulasta Onpro Competitor
September 27th 2023With the European Commission's (EC) approval of Tyruko, Europe receives its first natalizumab biosimilar and first biosimilar to treat multiple sclerosis (MS), while Coherus Biosciences received a complete response letter (CRL) for its biosimilar for Neulasta Onpro.
New Year, New Hurdles: What's in Store for Biosimilars in 2023
December 18th 2022On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.
Biosimilars Oncology Roundup for September 2022—Podcast Edition
October 2nd 2022On this episode of Not So Different, we take a look at some of the big stories regarding oncology biosimilars throughout the month of September, including 2 FDA approvals, and the withdrawal of a European application.
Despite Global Increase in Amjevita Sales, US Sales Dropped 63%
August 5th 2023Despite global sales for Amjevita (adalimumab-atto) growing by 29% year-over-year and the agent being the first adalimumab biosimilar on the US market, sales in the United States dropped 63% from the first quarter to the second quarter of 2023.
Abstracts Highlight Growing Comfortability With Trastuzumab Biosimilars in Breast Cancer
July 31st 2023Abstracts presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2023) emphasized the safety and efficacy of a trastuzumab biosimilar in treating HER2-positive breast cancer and growing utilization of trastuzumab biosimilars over time.
2 Clarke Drive
Cranbury, NJ 08512